https://www.kindredbio.com/ https://www.kindredbio.com/management-and-team/ https://www.kindredbio.com/
https://www.kindredbio.com/pipeline/ Kindred Biosciences to Present at Stifel 2020 Virtual Jaws & Paws Conference
May 13, 2020
SAN FRANCISCO , May 13, 2020 /PRNewswire/ -- Kindred Biosciences , Inc. (NASDAQ: ...
https://finviz.com/quote.ashx?t=kin&ty=c&ta=1&p=d Manufacturing 'Kindred Biosciences Inc (KIN)'
Kindred Biosciences Announces Completion of Mirataz® (mirtazapine transdermal ointment) Transaction
April 15, 2020
$KIN 07-29-2020 btm.Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart
May 20, 2020
San Francisco, California (May 20, 2020) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics,
today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.
“We are proud to be contributing toward the effort to develop a COVID-19 vaccine.
We look forward to working with Vaxart to bring this innovative technology to patients as quickly as possible,” said KindredBio’s Chief Executive Officer,
Richard Chin, M.D.
“This marks an important step in the development of our contract manufacturing business, which has the potential to help fund our promising pipeline.”
Under the terms of the agreement, KindredBio will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Burlingame, CA.
There, KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices,
and provide it to Vaxart to be
formulated into a vaccine tablet to be taken by mouth
instead of by needle injection.
KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.
“We are pleased to be partnering with Kindred Biosciences in the development of our oral COVID-19 vaccine candidate,” said Vaxart’s Chief Executive Officer,
Wouter Latour, M.D.
“We believe our novel approach utilizing a room temperature-stable tablet offers important logistical advantages in widespread oral vaccination,
and that KindredBio with its state-of-the-art manufacturing plants is
an ideal partner to realize our vision.”
KindredBio’s core expertise includes protein engineering,
cell line development,
master cell banking, process development, assay development, stability testing, and
cGMP clinical and
commercial manufacturing from 50 litres to 2,000 litres.
KindredBio’s manufacturing facilities provide a seamless transfer from
the research and development stage,
to the commercial manufacturing stage.
Our team maintains control over all steps and processes and provides
a unique setting for the development and manufacturing of high-quality, species-specific veterinary biologics.
High standards create dependability when your pet needs it most
The quality of our biologics and pharmaceuticals is just as important
as their development.
KindredBio will manufacture products under the appropriate
regulatory frameworks such as Title 9 and Title 21 of the Code of Federal Regulations for products being licensed through the
USDA and FDA respectively.
KindredBio manufacturing sites in Burlingame, CA and Elwood,
KS follow Current Good Manufacturing Practices (cGMP).
KindredBio acquired, retrofitted, and commissioned an additional manufacturing facility in Elwood, Kansas.
We are uniquely positioned to meet the manufacturing needs of
our promising pipeline with combined facilities reaching
180,000 square feet of full-spectrum production,
from infancy to commercialization,
including labeling and packaging end-to-end processes.
KindredBio Clinical and Commercial Manufacturing can support the production of a broad range of biologics and pharmaceuticals.
This is done through the use of single-use bioreactor
(SUB) up to 2,000L in size and the use of automated vial filling, labeling, and cartoning equipment providing flexibility throughout
In addition to the Kansas facility, KindredBio commissioned its own dedicated cGMP biologics manufacturing facility in close proximity
to our development labs in Burlingame, California.
The facility utilizes state-of-the-art single-use technology and
has the capacity to meet the requirements for the small scale
clinical and commercial KindredBio biologics supply.
KindredBio is one of the few biopharmaceutical manufacturers that
can capitalize on its production capacity and maintain a steady
revenue stream while ensuring all fulfillment needs are met.
KindredBio provides full service contract development and manufacturing activities,
which are managed by a wholly owned subsidiary, Centaur Biopharmaceutical Services.
$KIN https://www.otcmarkets.com/stock/KIN/disclosure https://www.otcmarkets.com/stock/KIN/news https://www.otcmarkets.com/stock/KIN/security KIN SECURITY DETAILS Market Cap Market Cap 197,244,065 02/01/2021 Authorized Shares.........Not Available Outstanding Shares......39,448,813 11/05/2020 https://www.otcmarkets.com/stock/KIN/profile https://www.otcmarkets.com/stock/KIN/quote https://www.otcmarkets.com/stock/KIN/overview
PER MGMT DAVE -
DISCLAIMER: ONLY FOR MICK
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any